Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr
Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu
FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund
FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh
First Quarter Results Filed: Creatd filed its Quarterly Report for the period ended March 31, 2026, reviewed by the Company's PCAOB-registered independent auditors, highlighting significant balance sheet developments following the disposition of Flyte.SEC Registration Progress: The Company has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission as part of its initiative to re-establish SEC reporting status.Annual Meeting Update: Creatd has revised the record date for its annual shareholder meeting to Friday, June 26, 2026, and the meeting date to Monday, August 3, 2026. Shareholders of record as of June 26, 2026, will be entitled to vote at the meeting
Partnership positions Flyte within elite professional sports ecosystem through leading talent agency GSE Worldwide Collaboration highlights growing demand for efficient regional travel solutions among professional athletes FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Flyte, the rapidly growing Regional Air Mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), today announced a partnership with sports and entertainment agency GSE Worldwide and PGA TOUR professional Emiliano Grillo that began this past weekend in the U.S. Open Championship. Grillo delivered an impressive performance at the 2026 U.S. Open, climbing as high as third place on the leaderboard during the champions
Strategic investors support Volato’s AI-driven aviation strategy and next phase of growth across software-enabled operating platforms Volato Group, Inc. (NYSE:SOAR) ("Volato" or the "Company") today announced the closing of a $2.2 million private investment in public equity ("PIPE") financing priced at $0.34 per share. The financing strengthens Volato’s balance sheet and provides additional capital flexibility as the Company advances its AI-focused strategy, including the application of its artificial intelligence technology, aviation operating experience, and software development capabilities to private aviation and other software-enabled markets. Volato is also evaluating acquisition,
S-1 - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)